Pituitary magnetic resonance imaging revealed an enlarged gland (24 × 13 × 12 mm), with extrasellar extension, and homogenous Acromegaly due to ectopic growth hormone-releasing hormone (GHRH) secretion from a neuroendocrine tumor (NET) is very rare, and up to 100 cases have been reported in the literature.
(LH, 8.9 U/l; FSH, 7.9 U/l; estradiol, 177 pg/ml) with regular menstrual cycles. No reduction in the pulmonary tumor size on CT was noted. The patient underwent a right upper lobectomy with clear tumor margins. A pathological report revealed a typical carcinoid with a mitotic count of less than 2 mitoses/2 mm 2 and absence of necrosis. Immunostaining was positive for chromogranin and CD56. Additional staining of the tumor showed high expression of GHRH and SSTR2 (80% of the cells) (FIGURE 1F and 1G) . The concentrations of GH and IGF -1 normalized after surgery (GH, 0.57 µg/l; IGF -1, 0.97 × ULN). No recurrence of acromegaly symptoms during a 3 -year follow -up was observed.
In summary, we reported a case of acromegaly with transient pituitary insufficiency due to GHRH -producing bronchial carcinoid causing somatotroph hyperplasia. A distinction between a pituitary somatotroph adenoma and ectopic GHRH secretion is important, as pituitary gadolinium enhancement without focal lesion (FIGURE 1B). As no pituitary adenoma could be detected, a chest X -ray was performed. A tumor (56 × 40 mm) in the right anterior mediastinum was identified. Chest computed tomography (CT) confirmed the presence of a 5 -cm tumor with calcifications and strong contrast enhancement (FIGURE 1C). Somatostatin receptor scintigraphy showed abnormal radiolabel uptake of the tumor revealed by CT (FIGURE 1D ). Long -acting somatostatin analogue treatment with lanreotide Autogel (120 mg) was started while awaiting surgery. A significant improvement in acromegaly symptoms was observed. After 3 months of treatment, pituitary imaging showed a reduction in the pituitary size (19 × 13 × 8 mm) (FIGURE 1E) associated by a decrease in GH and IGF -1 levels (GH, 6 µg/l; IGF--1, 1.4 × ULN), normalization of corticotroph function (ACTH 8:00 AM, 14 pg/ml; cortisol 8:00 AM, 9.4 µg/dl) and gonadotrophic function 
